

Exclusive Sponsor

Law Firm

FANGDA PARTNERS
方達律師事務所

Dataroom Support

ideals.

Media Support

BioVaXey
佰傲谷
生物医药知识聚合社区

 **医药魔方**
PHARMCUBE

 **eChinaHealth**
世易医健

 **动脉新医药**
VB-NeoBio

 **丁香园**

 **Insight**

 **药渡**
Pharmacodia



ADD: No.72 Huating Road, Xuhui District, Shanghai,
China 200030
TEL: +86-21-63331280
EMAIL: conference@bfcgroup.biz
WEBSITE: en.bfcgroup.biz

2025 BFC GLOBAL HEALTHCARE

**SUMMER BD &
INVESTMENT CONFERENCE**
BFC医疗健康夏季国际商务合作投资研讨会2025

Omni Boston Hotel at the Seaport
Sunday June 15th
2025 12:00-6:00 PM
奥姆尼波士顿海港酒店



COMPANY PROFILE	01 - 02
CONFERENCE AGENDA	03 - 04
SPEAKER BIOGRAPHIES	05 - 14
SPONSORS	15

BFC Group is a China-based boutique investment banking firm with a focus on mergers and acquisitions, licensing, financing, and regulatory affairs. We work with leading healthcare companies in the U.S., Europe, and Asia. With first-hand operational experience in both the U.S. and China, we have a deep understanding of challenges our clients face when establishing a company presence or expanding its presence outside its home market.

Strategy: Stay close to innovation and drive scientific breakthroughs through partnership.

Goal: Develop a strategic expansion model based on our clients' needs and implement it seamlessly in the target market.

Global Presence: Shanghai, Beijing, Hainan, Seoul, Tokyo, Mumbai, San Francisco, New York, London.

BFC Team: Consist of professionals from a diverse background in healthcare management in the U.S, Europe, and China. Our team members have a substantial scientific foundation and expertise, which gives us a strong edge in understanding our clients' products and technology. Our experience is enriched through a broad spectrum of practices ranging from discovery research, product development, product marketing and regulatory affairs to business development, investment banking, and venture investing in global markets.

At BFC, a close, collaborative working environment ensures that we deliver the best service to our clients. With international connections in an increasingly complex social, legal, and financial world, we initiate innovation, foster progress, and serve the global community.

Conference Agenda

June 15, 2025

12:00 – 13:00Registration

13:00 – 13:30Opening Remark – Cross-border Licensing Trends

Speaker:
David Chen, Managing Director, BFC Group

13:30 – 14:00Keynote Speech - Navigating Challenges in Quickly Shifting Landscapes: Strategic Partnering and Cross-Border Transactions in Life Sciences

Speaker:
Henry He, Partner, Fangda Partners

14:00 – 14:30Coffee Break

14:30 – 15:30Panel 1 - Biopharma Investment Landscape: What’s Driving Deals in 2025 and Beyond?

Moderator:
Michael Tung, MD, Chief Financial Officer, vTv Therapeutics

- Distinguished Speakers:
- Grace Han McMahon, Associate Vice President and Head, Pacific Business Development & Licensing, MSD
 - Venkatesan Raghavan, Executive Director Search & Evaluation – Oncology, Novartis
 - Tomohiro Yamauchi, Executive Director, Global Head of Scouting & Transaction Oncology, Astellas
 - Johan Verbeeck, Vice President Business Development, Oncology, Johnson & Johnson Innovative Medicine
 - Toby Freyman, Vice President, Business Development, Alexion Pharmaceuticals

15:30 – 15:45Coffee Break

15:45 – 16:45Panel 2 - Maximizing Global Value from Asia’s Early-Stage Biotech

Moderator:
Mitchell Zhang, Vice President, BFC Group

- Distinguished Speakers:
- Maha Radhakrishnan, Executive Partner, Sofinnova Investments
 - Christopher Hupp, Senior Director, External Innovation, Chemistry, Ipsen
 - Harish Soundararajan, Vice President, Roivant Sciences
 - Dan Zheng, Head of Regional Innovation and Partnerships, Center for External Innovation, Takeda
 - Tess Cameron, Principal, RA Capital

16:45 – 17:45Panel 3 - The Rise of Asian Biotech: Why Global Pharma is Betting Big?

Moderator:
Yuan Mi, Founder/COO, CytosinLab Therapeutics

- Distinguished Speakers:
- Cynthia Wang, Director, Global Business Development, Asia-Pacific Region, Servier
 - Josh Shin, Partner, Fangda Partners
 - Guoxin Zhu, Vice President, Molecule Discovery, Lilly Research Laboratories, Eli Lilly and Company
 - René Fuertig, Global Head of Neuroscience & Mental Health BD+L, Boehringer Ingelheim
 - Adrianne L. Wong, Director, Oncology Search & Evaluation of Global Business Development, Daiichi Sankyo



Adrianne L. Wong

*Director, Oncology Search & Evaluation of Global Business Development
Daiichi Sankyo*

Adrianne Wong is a developmental biology Ph.D. who loves drawing maps, asking questions, and matchmaking.

My journey encompasses roles in the academic, legal, non-profit and biopharma sectors, with experience building partnerships across the life sciences ecosystem.

As Director, Oncology Search & Evaluation at Daiichi Sankyo, Adrianne scouts globally for assets to complement our DXd-ADC portfolio. Adrianne entered pharma as an Alliance Manager for complex academic and pharma translational and clinical programs. Previously supported the development of platform technologies for global health infectious disease prevention at IAVI and led cell therapy and imaging biomarker programs and industry partnerships at JDRF. Counseled clients on life sciences intellectual property strategy and patent prosecution at Darby & Darby, P.C.. Translated high science into actionable insights and cool science stories for a range of stakeholders as a freelance science communicator and at NPR's Science Friday. NIH Postdoctoral Fellowship Columbia University, Ph.D. Duke University, B.A. Brown University.



Cynthia Wang

*Director, Global Business Development, Asia-Pacific Region
Servier*

Cynthia Wang Joined Servier China as Business Development Director since July 2015. Ever since April 2020, Cynthia serves as Global Business Development Director for Asia Pacific region, to co-create and drive innovation in therapeutic options

Cynthia brings with her over 20 years of Healthcare/pharmaceutical industrial experience in China. Prior to Servier China, Cynthia worked at Pfizer Strategy and Business Development for Vaccine BD global M&A projects and managing full TAs out-licensing BD activities. Before joining Pfizer, Cynthia held a series of positions in Business Development, New Product Introduction, Product launch, Strategic Alliance Management, Business planning and Operational Management at Janssen/Johnson & Johnson and Agilent Technologies. Cynthia has broad BD network in China serving as Rotating Chairperson of CHBD(China Healthcare BD) organization and China Healthcare development(expert) committee member, Cynthia has proven BD track records of closing multiple BD deals.

Cynthia holds a Master of Business Administration from Peking University, a Master of Global Finance from Fordham University in NYC, a Pharmacy degree from Peking University Health Science Centre.



Christopher Hupp

*Senior Director, External Innovation, Chemistry
Ipsen*

Christopher Hupp is currently Senior Director of Research and External Innovation at Ipsen Biopharmaceuticals, in Cambridge MA. Over the last four years, he has been part of a team that's responsible for identifying and fostering innovative opportunities that align with Ipsen's strategic goals, driving forward the company's mission to improve patients' lives through transformative therapies. As part of the External Innovation team, Chris actively engages with external partners, including academic institutions, biotech companies, and research organizations, to scout and evaluate new technologies and therapeutic approaches. Last year, Chris was instrumental in bringing in Ipsen's first strategic partnership with a Chinese biotech, Foreseen Biotechnology.

Prior to joining Ipsen, Chris spent 11 years at X-Chem in several roles, including the coordination and management of chemistry efforts across multiple programs, leading interactions with external partners across therapeutic areas and providing chemistry leadership on X-Chem's internal projects. Chris completed a post-doctoral research fellowship at Harvard Medical School/McLean Hospital and holds a PhD in Organic Chemistry from Michigan State University.



Dan Zheng

*Head of Regional Innovation and Partnerships, Center for External
Innovation
Takeda*

Dan currently serves as the Head of Regional Innovation and Partnerships at Center for External Innovation at Takeda, where she is responsible for building relationships and mutually beneficial strategic partnerships in regional ecosystems. Prior to this, she spent over 10 years in business development in Takeda and Sanofi and has led transactions across different therapeutic areas, platform technologies, and asset stages with total deal value over \$6B. She started her corporate career at Sanofi in 2014 in Asia where she was instrumental in defining the China strategic roadmap, identifying and evaluating BD opportunities, and executing priority deals. Prior to Sanofi, Dan was a management consultant at ZS Associates where she focused on advising the top global pharmaceutical companies on a broad range of business issues from strategy to operations. Dan holds a PhD in Biological Sciences from Northwestern University and a BS from Nanjing University in Biochemistry.



David Chen

*Managing Director
BFC Group*

Over 20 years of BD and M&A experience in pharmaceutical, diagnostic and medical devices companies in both the US and China. Led many cross-border deals by creatively bridging differences among different parties.

Former scientist at Bayer Corporation, BD at Eli Lilly in the US, and CFO at Shanghai Sunway Biotech.

Frequent speaker at various investment conferences.

MBA from Northwestern University (Kellogg), M.S. in biochemistry from Rutgers University, B.S. from Zhejiang University.



Guoxin Zhu

*Vice President, Molecule Discovery, Lilly Research Laboratories
Eli Lilly and Company*

Dr. Guoxin Zhu, Vice President of Molecule Discovery at Lilly Research Laboratories, is responsible for overseeing the search, evaluation, business development, and deal-making in small molecule research across various therapeutic areas.

After serving as a laboratory head in Indianapolis, Dr. Zhu took on an international assignment, leading Lilly's research efforts in China as the head of China Research from August 2005 to August 2007. Upon returning to Lilly's corporate center in 2007, Dr. Zhu has held various leadership positions, including Chief Operating Officer of the chemistry department, Inclusion Leader of Lilly Research Laboratories Human Resources, and Chief Scientific Officer of Medicinal Chemistry. For more than a decade, he has been responsible for managing the small molecule discovery chemistry portfolio strategy, ensuring scientific rigor in project milestone decisions, driving externalization innovation strategy, and overseeing key business transformations across the entire small molecule portfolio at Lilly. He serves as a member of various scientific governance committees across all modalities for key decision points.

Dr. Zhu earned his bachelor's degree from Hangzhou University and obtained his doctorate in organic chemistry from the Shanghai Institute of Organic Chemistry, the Chinese Academy of Sciences. After completing postdoctoral research at Pennsylvania State University, he joined Lilly Research Laboratories in 1998 as a Senior Organic Chemist. During his early tenure at Lilly, Dr. Zhu has made substantial scientific contributions to metabolic disease and oncology research, including co-inventing a phase 2 clinical compound for a positive PoC.



Grace Han McMahon

*Associate Vice President and Head, Pacific Business Development & Licensing
MSD*

Grace Han McMahon leads the Pacific Business Development & Licensing team for Merck & Co., Inc., Rahway, NJ, USA (MSD). She and her team are based in South San Francisco, California, Shanghai and Tokyo. The Pacific team focuses on early stage therapeutic opportunities with companies and universities in China, Japan, Korea, Singapore, Australia, New Zealand, India and the west coast of North America. Grace has more than 20 years of biopharma experience having started her career at MSD's headquarters in New Jersey. She joined Genentech in 2013 where she led a team of lawyers focused on licensing, M&A and manufacturing deals. Grace re-joined MSD in 2018 to lead Transactions for MSD's west coast based BD&L team and took on responsibility for the search and evaluation team in 2021. Grace serves on the Board of California Life Sciences and is a member of the Council for Korean Americans. Grace holds an M.B.A. from INSEAD, a J.D. from New York University School of Law and a B.A. from the University of Virginia. She enjoys swimming and cycling and is an avid baseball fan.



Harish Soundararajan

*Vice President
Roivant Sciences*

Harish Soundararajan, PhD, is Vice President of Investments at Roivant Sciences, where he leads a team focused on acquiring and licensing innovative pharmaceutical assets. Prior to Roivant, Harish was a Managing Director at Marshall Wace, where he invested across public and private healthcare companies, including therapeutics, diagnostics, devices, and services. He started his healthcare investment journey at Farallon Capital Management, where he was a healthcare investor across private growth-stage and public opportunities. Earlier in his career, he was a strategy consultant at McKinsey & Company, advising leading global biopharma clients. Harish holds a PhD in Biological Sciences from the University of Cambridge and completed his postdoctoral research at Harvard Medical School and the Wyss Institute.



Henry He

Partner
Fangda Partners

Mr. He specializes in cross-border transactions involving complex business, intellectual property, operational and legal issues, including strategic partnerships, product and technology licensing (in/out), asset acquisitions and divestitures, platform discovery and option deals. Additionally, Mr. He counsels life sciences clients on day-to-day operational and regulatory matters involving clinical trials, investigator-initiated trial (IIT), regulatory and HGR (human genetic resources) compliance, drug supply and promotion, research and commercialization collaborations.

Mr. He joined Fangda as a partner in 2023. Prior to joining the firm, Mr. He worked as the Board Secretary, Associate Vice President and General Counsel at CStone Pharmaceuticals (2616.HK). Before moving in-house, Mr. He had worked at two reputable international law firms (Cooley LLP and Baker & McKenzie LLP) for many years, representing venture capital funds, emerging companies and multinational corporations with exposure to early-stage financing and pre-IPO restructuring, licensing, venture capital, offshore/onshore ESOP matters and corporate M&A.



Josh Shin

Partner
Fangda Partners

Mr. Josh Shin boasts over 20 years of experience in M&A, equity financing, regulatory advisory, and general corporate work, with a strong focus on life science and healthcare industries. Leading the healthcare practice within the firm's corporate group, Josh is well-versed in advising clients on a wide range of legal matters within the life sciences sector.

Josh has played a key role in steering various life sciences transactions, including licensing, collaboration, M&A, and equity finance deals. His "good business sense" and keen understanding of client needs have earned him praise from those he has worked with. Additionally, Josh has a proven track record in providing regulatory advice on cutting-edge legal issues in life sciences industry. Josh's clientele commended him that "Finding someone who always has sight of the bigger picture while diving into the smallest details to ensure the quality of work product is not easy. Josh has distinguished himself for his professionalism, enthusiasm to the career and sensitivity of industry".



Johan Verbeeck, DVM

Vice President Business Development, Oncology
Johnson & Johnson Innovative Medicine

Johan Verbeeck is Vice President, Business Development, Oncology for Johnson & Johnson. In this role, Johan leads all business development activities for this therapeutic area and has accountability for Oncology transactions, acquisitions, scientific licensing and alliance management. His team completed multiple transactions in this space, including the \$2B acquisition of Ambrx Pharmaceuticals in 2023.

Prior to his current position, Johan was Vice President, Business Development, Immunology, where he was involved in the identification and evaluation of multiple opportunities which resulted in partnerships with e.g., Protagonist Therapeutics for its oral IL-23 inhibitor and Theravance Pharmaceuticals for their gut-restricted pan-JAK inhibitor, as well as the \$6.5B acquisition of Momenta Pharmaceuticals in 2020.

Johan joined Johnson & Johnson in 1996, through Janssen Pharmaceutica in Belgium, in the Department of Animal Health and subsequently worked in Toxicology, where he became a Study Director for a multitude of small molecule development projects. In 2005, Johan joined Tibotec, as Lead Toxicologist for the development of Prezista® and Intelence®, the company's first two approved anti-HIV drugs. At the same time, he was Preclinical Development Leader for bedaquiline, the first new drug in development for tuberculosis in over 40 years. For the latter program, he received the Johnson & Johnson Medal for Research and Development in 2013. In 2007, after the approval of Intelence, Johan became Head of Toxicology Sciences for Janssen Research & Development. He also served as Alliance Manager in the External Alliances and Business Models group.

Prior to joining the Janssen Business Development team, Johan joined the London Innovation Center in 2013 as one of its first members and played an active role in helping to establish the center, building its European network and securing several transactions.

Johan holds a Doctorate in Veterinary Medicine from the University of Gent, Belgium. He also graduated Cum Laude with a Master of Science in Applied Toxicology from the University of Surrey, United Kingdom.



Maha Radhakrishnan, MD

Executive Partner
Sofinnova Investments

Maha Radhakrishnan, M.D is currently Executive Partner at Sofinnova Investments and in her most recent role was Consultant to the CEO at Dyne Therapeutics helping with the overarching strategy and direction to the company R&D and Commercialization efforts. Prior to that she was the Chief Medical Officer at Biogen, responsible for the Worldwide Medical function since rejoining Biogen in January 2020.

Previously, from 2016-2019, Dr. Radhakrishnan was Senior Vice President and Global Head of Medical, Primary Care Business Unit at Sanofi, a global biopharmaceutical company focused on human health. At Sanofi, she led the medical strategy and operations for the diabetes and cardiovascular products and development programs. Prior to this, she held several key leadership roles at Bioverativ Inc. from 2016-2018, Biogen for the first time from 2013-2016, Bristol Myers Squibb from 2009-2013, United Health Group from 2006-2008, and Cephalon from 2005-2006.

Dr. Radhakrishnan has extensive experience in overseeing the medical strategy development, external scientific engagement strategy with academic institutions, top and emerging key opinion leaders, patient advocacy groups, media, investors, payers, policy makers, government, and regulators. She has overseen the launch preparations and execution of several blockbuster launches including Abilify, Orencia, Tecfidera, Praluent, Nusinersen, Qalsody, Leqembi, Skyclarys and Clinical Development including life cycle management of several critical programs in the Hemophilia, Immunology, Rare Disease, Cardiovascular and CNS Therapeutic areas.

She received her M.D. in internal medicine with honors from the People's Friendship University in Moscow, Russia in 1995, as well as a master's degree in Russian language. She is also a certified Russian language instructor and interpreter.



Michael Tung, MD

*Chief Financial Officer
vTv Therapeutics*

Michael brings more than 20 years of financial management, investment experience, and strategic leadership for both private and public companies in the life sciences industry. Prior to joining vTv Therapeutics, Dr. Tung most recently served as Chief Financial Officer of AdvanCell Pty Limited. He also held senior level positions in corporate strategy and investor relations at FibroGen Inc. and Aclaris Therapeutics. Earlier in his career, he led the portfolio construction and risk management of healthcare-dedicated funds as a Portfolio Manager at multiple firms. Dr. Tung earned B.A. and B.S. degrees in economics and biology, respectively, from The George Washington University, and a combined M.D./M.B.A. degree from Tufts University School of Medicine. He is a licensed physician in the states of Massachusetts



René Fuertig

*Global Head of Neuroscience & Mental Health BD+L
Boehringer Ingelheim*

Dr. René Fuertig is Global Head of Neuroscience & Mental Health BD+L at Boehringer Ingelheim based in Germany. In this role, together with his fantastic team they are scouting for breakthrough opportunities around the globe to find novel treatment approaches to mental health disorders / specific psychiatric symptom domains, central mechanisms of pain and neurodegeneration.

Dr. René Fuertig is a scientist and drug development expert with over 10 years of R&D experience. Dr. René Fuertig has studied pharmacy at the University of Halle-Wittenberg and did his PhD at Boehringer Ingelheim in collaboration with the University of Ulm in the area of biomarkers in relation to chronic psychosocial stress. René also holds an MBA from Goethe Business School in Frankfurt, Germany. After his PhD, Dr. René Fuertig held several positions at Boehringer Ingelheim, first in Translational Medicine and Clinical Pharmacology where he was responsible for Clinical Pharmacology as well as Translational Strategies in preclinical & clinical drug development projects. Later on, he was International Project Leader and early Asset Lead responsible for leading preclinical and clinical asset teams, mainly in the field of CNS / Mental Health disorders. Since 2022, Dr. René Fuertig led due diligences of preclinical and clinical stage in-licensing opportunities in the fields of Oncology, Cardio-Renal Metabolism and CNS. René joined Business Development & Licensing at Boehringer Ingelheim in 2024 where he holds the position of Global Head of Neuroscience & Mental Health BD+L.

Dr. René Fuertig is passionate about innovation and science related to precision psychiatry which is aimed at redefining mental healthcare to enable people to thrive.



Mitchell Zhang

*Vice President
BFC Group*

Mitchell Zhang is a CICPA and CFA certified professional with a strong track record in cross-border transactions within the biotech industry. He has extensive project experience across various therapeutic areas, particularly in oncology, metabolic diseases, and autoimmune diseases. Mitchell led the licensing transaction between Chengdu Baiyu and Novartis for an oncology small molecule, the NewCo transaction for CD38 monoclonal antibody between Keymed Bio and Timberlyne, and the licensing deal for a hexavalent VLP norovirus vaccine between HilleVax, a NASDAQ-listed U.S. biotech, and Chengdu Kanghua, a listed Chinese vaccine company. Mitchell has been at the forefront of leading multiple cross-border deals, with a cumulative transaction value exceeding \$1 billion.

Prior to joining BFC Group, Mitchell worked as the Corporate Strategy & Business Development Manager at Ping An Health (stock code: 01833.HK), a leading online medical and healthcare service platform in China. He also served at Ernst Young and Deloitte, providing comprehensive accounting and financial advisory services to business overseas within Pharmaceutical, Healthcare, Consumer Retail and Energy Industries.

Mitchell holds a Bachelor's degree in Business Administration from Emory University Goizuetta Business School and an MBA in Finance from China Europe International Business School (CEIBS).



Tess Cameron

*Principal
RA Capital*

Tess Cameron is a Principal on the Investment Team at RA Capital Management. Tess works on both public and private investments and serves on several company boards. Previously, Tess held finance leadership roles at Foghorn Therapeutics, Wave Life Sciences, and Biogen. Prior to joining biotech/pharma, she was a specialist in the corporate finance team at McKinsey & Co, focused on corporate transactions. Tess holds a BA with a double major in Economics and Peace & Conflict studies from the University of Toronto, Canada.



Toby Freyman

*Vice President, Business Development
Alexion Pharmaceuticals*

Dr. Freyman has over 20 years of experience in the healthcare industry. During this time, he developed expertise in organizational leadership, defining strategic priorities, and business development to build biotech and pharmaceutical pipelines and product portfolios. In addition to leading several business development teams, Toby has championed and closed many different investments and buy-side and sell-side transactions across a range of different deal types.

He is currently Vice President, Business Development at Alexion, AstraZeneca Rare Disease. Prior to this, he worked at other large and small companies, including BeiGene, Takeda, Shire, Lyra Therapeutics (formerly Arsenal Medical), and Boston Scientific. He also worked as a business consultant at CRA International developing commercial launch and market access strategies for biotech and pharmaceutical products. Toby holds a B.S. from Syracuse University and a Ph.D. in Materials Engineering from MIT, where he received an NIH Graduate Fellowship through a joint program with Harvard and MIT.



Tomohiro Yamauchi

*Executive Director, Global Head of Scouting & Transaction Oncology
Astellas*

Dr. Yamauchi has worked at Astellas for 17+ years in various roles with increasing responsibility in Business Development, R&D, Corporate and Portfolio Strategy to lead multiple business transactions (including M&A, in-/out-licensing, new company creation, asset sale, clinical combo trial collaboration and CDx collaboration), pipeline prioritization and portfolio management. He has more than 10 years' experience of research in oncology and published several scientific papers in well-recognized journals, including EMBO J. and Clinical Cancer Res. Prior to joining Astellas, he served as a research associate in RIKEN, Japan, and obtained a Ph.D. in Medicine from Tsukuba University and also had the clinical pharmacist license in Japan.



Venkatesan Raghavan

*Executive Director Search & Evaluation – Oncology
Novartis*

Dr. Venky Raghavan leads Search and Evaluation for prostate and breast cancer at Novartis, and in this role he is responsible for finding core opportunities to continue to build Novartis' pipeline beyond Pluvicto and Kisqali. Venky joined Novartis in early 2024, and prior to his present role was the senior director of S&E for solid tumors at Bayer, and spent over five years at Bayer in roles spanning marketing and BD&L. Prior to his career at Bayer, Venky was a management consultant with Oliver Wyman where he advised clients on strategic and portfolio management projects. Venky has a PhD in Molecular Biology from the University of Pittsburgh School of Medicine.



Yuan Mi

*Founder/COO
CytosinLab Therapeutics*

Dr. Yuan Mi is the Co-founder and COO of CytosinLab Therapeutics. Dr. Mi obtained his B.S. from Peking University, Ph.D. from University of Michigan, and did a post-doc with Professor E.J. Corey, a Nobel Chemistry Laureate. He has more than 20 years of experience in drug discovery and development, delivering multiple drugs into clinical development. Dr. Mi is the inventor of nearly 40 granted patents and has published numerous articles in peer-reviewed journals. Before co-founding CytosinLab, Dr. Mi was Director of MedChem and Scientific Operations at Novartis Institutes for Biomedical Research (NIBR), and accumulated rich experience in drug discovery and development, operations, and building high-performance team.

ACHIEVING EXCELLENCE



1993

Founded in 1993, Fangda Partners is a full-service law firm advising on PRC and Hong Kong laws



Our outstanding team consists of nearly 182 partners and nearly 800 lawyers



Our clients include domestic and foreign Unicorns, head institutions, multinational corporations, high-growth companies, etc.



Our recognitions by the most authoritative legal directories in the world:

Chambers&Partners Great China, 2025
30 ranked practice areas
75 recognized lawyers

The Legal 500 Asia Pacific, 2025
30 ranked practice areas
55 recognized lawyers

Benchmark Litigation Asia-Pacific, 2025
7 recognized practice areas
11 recommended partners



As one of the most prestigious law firms in the region, Fangda constantly receives various awards and top rankings in Life Sciences & Healthcare and PEVC practice, including:

- ◆ **Healthcare and Life Sciences: PRC Firms- Tier 1**
The Legal 500, Asia Pacific- China (Mainland), 2019-2025
- ◆ **Pharmaceuticals and life sciences: Highly recommended**
Asialaw Profiles, China, 2024-2025
- ◆ **Healthcare: PRC Firms - Band 2**
Chambers, Greater China Region Guide, 2022-2025
Chambers, Asia-Pacific Guide, 2019-2021
- ◆ **Healthcare & Life Science Firm of the Year - China**
China Law & Practice Awards, 2021&2022
- ◆ **Private Equity & Venture Capital Investment: PRC Firms-Band 1**
Chambers, Greater China Region Guide, 2022-2025
Chambers, Asia-Pacific Guide, 2018-2021
- ◆ **Winner of Private Equity & Venture Capital China Business Law Awards, China Business Law Journal, 2020-2024**
- ◆ **Corporate/M&A: PRC Firms- Band 1**
Chambers, Global Guide, 2020-2025
- ◆ **Deal of the year - Corporate & M&A: PRC Firms**
The Legal 500 China Awards, 2024



We are at the forefront of every area of focus:

- | | | |
|----------------------------|--|----------------------------|
| Antitrust/ Competition | Asset-backed Securities | Banking & Finance |
| Capital Markets | Compliance & Government Enforcement | Dispute Resolution |
| Energy & Infrastructure | Financial Industry | General Industries |
| Insolvency & Restructuring | Intellectual Property | Investment Funds |
| Investment Management | Labor & Employment | Life Sciences & Healthcare |
| M&A | Private Equity | Private Wealth Management |
| Tax | Technology, Media & Telecommunications | Real Estate & Construction |
| | | Japan Practice |